About AbbVie
AbbVie is a publicly listed company based in Chicago (United States) founded in 2012. Biopharmaceutical research and drug development are conducted globally by AbbVie. The company has 55,000 employees. AbbVie has completed 18 acquisitions, including AMAL Therapeutics, Aliada Therapeutics and Allergan. Its website abbvie.com draws about 852 thousand monthly visits. Its Indian entity Abbvie Therapeutics India Private Limited reported revenue of ₹533 Cr. Its focus areas include Diversified Pharmaceuticals and Drugs. Similar companies include Roivant Sciences, Gilead and Lilly; 1 of its 3 listed similar companies has raised funding.
Company details
AbbVie was established in 2012 and is based in Chicago, United States, within the biopharmaceutical sector. Global operations involve the creation of treatments for autoimmune diseases and other conditions, including adalimumab marketed as Humira, alongside AndroGel, Kaletra, and Norvir. Medicines are distributed worldwide through research-driven processes. In 2022, revenues totaling 56.74 billion were reported, with net profits reaching 7.54 billion.
- Headquarters Chicago, United States
- Employees 55,000
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website abbvie.com
- Social LinkedIn X Facebook
- Legal Name Abbvie Inc.
- Indian entity revenue₹533 Cr
FY 2026 · +5% YoY
- Indian entity net profit₹126 Cr
FY 2026 · 24% margin
- Indian entity EBITDA₹177 Cr
FY 2026 · 33% margin
- Latest Funding Round$5.9B (USD), Debt – Conventional
Oct 2018
- Employee Count55,000
- Investments & AcquisitionsAMAL Therapeutics
& 17 more
Associated legal entities of AbbVie
AbbVie operates through Abbvie Therapeutics India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Abbvie Therapeutics India Private Limited CIN U33201KA1994PTC023162 | Active | 04 Jul 1994 | Bangalore, Karnataka | ₹533 Cr | 386 | 8 | View details |
Apps and channels of AbbVie
AbbVie publishes 1 mobile app with over 100K+ downloads.
Funding Insights of AbbVie
- Total Rounds 3
- Last Round Debt – Conventional — $5.9B
- First Round $14.7B
(Nov 2012)
All 3 funding rounds of AbbVie with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2018 | $5.9B | Debt – Conventional | – | – | – |
| Jun 2018 | $3B | Debt – Conventional | – | – | – |
| Nov 2012 | $14.7B | Post-IPO | – | – | – |
Board of directors of Abbvie Therapeutics India Private Limited (AbbVie)
Abbvie Therapeutics India Private Limited is the primary company behind AbbVie. The board of Abbvie Therapeutics India Private Limited currently have 7 directors; the longest-serving is Swati Ajay Piramal, appointed in 2002. 32 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Swati Ajay Piramal DIN 00067125 | Director | 26 Mar 2002 | 24 yrs 7 mo | Abbvie Therapeutics India Private Limited |
| Ajay Gopikisan Piramal DIN 00028116 | Director | 29 Sep 2015 | 11 yrs 1 mo | Abbvie Therapeutics India Private Limited |
| Suresh Pattathil DIN 02748206 | Managing Director | 10 Jul 2020 | 6 yrs 3 mo | Abbvie Therapeutics India Private Limited |
| Vivek Valsaraj DIN 06970246 | Director | 22 Feb 2022 | 4 yrs 8 mo | Abbvie Therapeutics India Private Limited |
| Vidhan Kedia DIN 06718606 | Director | 24 Jan 2023 | 3 yrs 9 mo | Abbvie Therapeutics India Private Limited |
| Anup Arvind Godbole DIN 09342708 | Director | 04 Dec 2025 | 11 mo | Abbvie Therapeutics India Private Limited |
| Jason Jay Dsilva DIN 11812727 | Additional Director | 27 Jul 2026 | 3 mo | Abbvie Therapeutics India Private Limited |
People of AbbVie
1491 people are tracked at AbbVie (744 in leadership, 12 in board & advisors, 735 in team); the tracked headcount is 55,000.
| Name | Role | Group |
|---|---|---|
Steve Schultz | Vice President | Leadership |
Dana Overbey | Global Sr Director Vendor Management Office And Technology Asset Management | Leadership |
Lauren Yarnell | Executive Assistant To The Svp, Abbvie & President, Specialty & U.s. Therapeutics Operations | Leadership |
Martin Hayes | Chief Of Staff, Global Neuroscience & Ophthalmology Research | Leadership |
Brad Pignatello | Director Ii, Payer Strategy Eye Care - US Market Access | Leadership |
Bruce Dannan | Director, Commercial Business Technology | Leadership |
Aimee Marx | Head Of Marketing US Patient Services | Leadership |
Bardia Akbari | Vice President - Development Operations Oncology | Leadership |
Sarah Cantor | Marketing Director - Access, Advocacy, And Non-retail | Leadership |
Nisha Patel Burns | Senior Vice President, AbbVie and President, Specialty and U.S. Therapeutics Operations | Leadership |
Michael Schaffer | Director Ii, Neurology Franchise Lead | Leadership |
Mohamed Haytham | General Manager - North Africa | Leadership |
Amanda Arlis | Director | Leadership |
Katie Stromsborg | Director Of Business Training And Development | Leadership |
Ana Alzugaray Beitia | CFO Spain | Leadership |
Alicia Subasinghe | Senior Director, Patient Advocacy | Leadership |
April Hughes | Associate Marketing Director, Immunology | Leadership |
Paula Lima | Oncology Patient (consumer) Marketing Associate Director | Leadership |
Cormac Dalton | Vice President Sterile Manufacturing | Leadership |
Edgar Torres | Director, Transformation | Leadership |
1471 more people are available in the full profile.
Complete people profiles for AbbVie
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of AbbVie
AbbVie is a publicly listed company on the NYSE with ticker symbol ABBV in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Apr 2021
- Listed onLSE: 0QCV
- Listed entityAbbVie Inc.
- Exchange sectorHealth technology
- ISINUS00287Y1091
- Share price$274.36 (-2.4% on the day) · 2026-10-13
- Market capitalisation$484.83B
- Price to earnings77.6
- EPS (diluted, trailing year)$3.54
- Dividend yield2.49%
- Volume (last session)6,409,514
Financials of AbbVie
Figures of Abbvie Therapeutics India Private Limited, the primary company behind AbbVie, for FY 2026. Revenue was ₹533 Cr (+5% year on year). Net profit was ₹126 Cr (24% margin). EBITDA was ₹177 Cr (33% margin). Revenue has grown at a compounded annual rate of +5% over three years and +7% over five years.
- ₹533 CrRevenue · FY 2026 · +5% YoY
- ₹126 CrNet profit · 24% margin
- ₹177 CrEBITDA · 33% margin
- ₹8.00 CrPaid-up capital
- 386Employees (provident fund records)
- +5%Revenue CAGR, 3 years
- +7%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $61.16B | $4.19B | $29.05B |
| 2024 | $56.33B | $4.24B | $25.01B |
| 2023 | $54.32B | $4.82B | $26.78B |
| 2022 | $58.05B | $11.78B | $31.07B |
| 2021 | $56.20B | $11.47B | $28.27B |
Balance sheet, profit and loss, cash flow and ratios of Abbvie Therapeutics India Private Limited are on its company page.
Detailed financial statements for AbbVie
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AbbVie
AbbVie has strategically engaged in corporate development activities, having acquired 18 companies. Notable acquisitions include AMAL Therapeutics, Aliada Therapeutics and Allergan.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of therapeutics for immunological and inflammatory disorders | apogeetherapeutics.com | Waltham, United States | 2022 | Jun 2026 | $10.9B | |
Cell therapies are developed for oncology and other diseases. | capstantx.com | San Diego, United States | 2021 | Jul 2025 | $2.1B | |
Combinatorial chemistry services for peptide-based drug discovery are provided. | nimbletherapeutics.com | Madison, United States | 2019 | Dec 2024 | $200M | |
Provider of drug research & development services for multiple therapeutic areas | aliadatx.com | Boston, United States | 2021 | Oct 2024 | $1.4B | |
Single-cell RNA and genomic analysis for precision therapeutics are provided. | celsiustx.com | Cambridge, United States | 2018 | Jun 2024 | $250M | |
Small molecule therapeutics for autoimmune diseases are developed. | landosbiopharma.com | Blacksburg, United States | 2016 | Mar 2024 | $212.5M | |
Therapeutics for neurological and neuropsychiatric disorders are developed. | cerevel.com | Boston, United States | 2018 | Dec 2023 | $8.7B | |
Prescription medicine treats adults with folate receptor-alpha positive ovarian cancers. | elahere.com | Waltham, United States | 2018 | Nov 2023 | •••• | |
Proprietary antibody-drug conjugates are developed for cancer treatment. | immunogen.com | Waltham, United States | 1981 | Nov 2023 | $10.1B | |
PINK1-targeted kinetins for Parkinson's and cardiomyopathy are developed. | mitokinin.com | New York, United States | 2012 | Oct 2023 | $110M |
Complete acquisition details for AbbVie
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of AbbVie
14 dated milestones of AbbVie across 14 years, from founding to its latest funding, stage changes and deals.
- Founded AbbVie is founded.
- Funding First funding round of $14.7B.
- Funding Latest funding round, Debt – Conventional, of $5.9B.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Mitokinin.
- Acquisition Acquires ELAHERE.
- Acquisition Acquires ImmunoGen.
- Acquisition Acquires Cerevel Therapeutics.
- Acquisition Acquires Landos Biopharma.
- Acquisition Acquires Celsius Therapeutics.
- Acquisition Acquires Aliada Therapeutics.
- Acquisition Acquires Nimble Therapeutics.
- Acquisition Acquires Capstan Therapeutics.
- Acquisition Acquires Apogee Therapeutics.
Similar companies to AbbVie
AbbVie has 3 listed similar companies in our database, 1 of them funded. They include Roivant Sciences, Gilead and Lilly.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| gilead.com | 1987 | Foster, United States | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | ||
| lilly.com | 1876 | United States | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. |
Detailed similar companies of AbbVie
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AbbVie
The website of AbbVie (abbvie.com) receives about 851.9K visits a month and ranks #69,141 among all websites worldwide, #1,925 in Biotechnology and Pharmaceuticals.
- Monthly visits851.9K
▲ 18.7% vs previous month
- Unique visitors303.6K
per month
- Global rank#69,141
among all websites
- Category rank#1,925
Health · Biotechnology and Pharmaceuticals
- Bounce rate47%
- Pages per visit3.1
- Average visit1 min 46 sec
- DevicesDesktop 60% · Mobile 40%
Websites whose visitors overlap most with AbbVie. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pfizer.com | 100% | 1.9M | #24,984 | View details | |
| merck.com | 98% | 656.8K | #78,842 | View details | |
abbvie.sharepoint.com | abbvie.sharepoint.com | 97% | – | ||
| novartis.com | 97% | 948.8K | #58,822 | View details | |
careers.lilly.com | careers.lilly.com | 96% | #60,411 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for AbbVie
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as AbbVie (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | USD 65.18 B | 47,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Abbvie
Complete news archive for AbbVie
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AbbVie
AbbVie was founded in 2012.
AbbVie is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
AbbVie has 55,000 employees.
The primary company behind AbbVie, Abbvie Therapeutics India Private Limited, reported revenue of ₹533 Cr for FY 2026, up 5% year on year.
AbbVie was established in 2012 and is based in Chicago, United States, within the biopharmaceutical sector. Global operations involve the creation of treatments for autoimmune diseases and other conditions, including adalimumab marketed as Humira, alongside AndroGel, Kaletra, and Norvir. Medicines are distributed worldwide through research-driven processes. In 2022, revenues totaling 56.74 billion were reported, with net profits reaching 7.54 billion.
AbbVie's top competitors include Roivant Sciences, Lilly and Gilead.
Yes, AbbVie is publicly traded on NYSE under the ticker symbol ABBV.
AbbVie has made 18 acquisitions, including AMAL Therapeutics, Aliada Therapeutics, and Allergan.
AbbVie operates through Abbvie Therapeutics India Private Limited.
The legal entities of AbbVie currently have 8 directors, including Swati Ajay Piramal, Suresh Pattathil, Ajay Gopikisan Piramal and others.
Yes. AbbVie publishes Complete – Medication Tracker, with over 100,000 downloads.
The website of AbbVie receives about 852 thousand visits a month and ranks #69,141 among all websites worldwide.